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Nonsteroidal anti-inflammatory drugs, besides exerting detrimental effects on the 
upper digestive tract, can also damage the small and large intestine. Although the 
underlying mechanisms remain unclear, there is evidence that enteric bacteria play a 
pivotal role. The present study examined the enteroprotective effects of a delayed-
release formulation of rifaximin-EIR (R-EIR, 50 mg/kg BID, i.g.), a poorly absorbed 
antibiotic with a broad spectrum of antibacterial activity, in a rat model of enteropathy 
induced by indomethacin (IND, 1.5 mg/kg BID for 14 days) administration. R-EIR was 
administered starting 7 days before or in concomitance with IND administration. At 
the end of treatments, blood samples were collected to evaluate hemoglobin (Hb) 
concentration (as an index of digestive bleeding). Small intestine was processed for: 1) 
histological assessment of intestinal damage (percentage length of lesions over the 
total length examined); 2) assay of tissue myeloperoxidase (MPO) and TNF levels, as 
markers of inflammation; 3) assay of tissue malondialdehyde (MDA) and protein 
carbonyl concentrations, as an index of lipid and protein peroxidation, respectively; 4) 
evaluation of the major bacterial phyla. IND significantly decreased Hb levels, this 
effect being significantly blunted by R-EIR. IND also induced the occurrence of lesions 
in the jejunum and ileum. In both intestinal regions, R-EIR significantly reduced the 
percentage of lesions, as compared with rats receiving IND alone. Either the markers of 
inflammation and tissue peroxidation were significantly increased in jejunum and 
ileum from IND-treated rats. However, in rats treated with R-EIR, these parameters 
were not significantly different from those observed in controls.  R-EIR was also able to 
counterbalance the increase in Proteobacteria and Firmicutes abundance induced by 
INDO. R-EIR treatment significantly prevents IND-induced intestinal damage, this 
enteroprotective effect being associated with a decrease in tissue inflammation, 
oxidative stress and digestive bleeding as well as reversal of NSAID-induced alterations 
in bacterial population. 
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Nonsteroidal anti-inflammatory drugs (NSAIDs) are very effective medications [1,2], 
but their use is associated with a broad spectrum of adverse reactions involving the 
liver, kidney, cardiovascular (CV) system, skin and gut [3]. Gastrointestinal (GI) adverse 
effects are the most common and cover a wide clinical spectrum, ranging from 
dyspepsia, heartburn and abdominal discomfort to more serious events, such as peptic 
ulcer with life-threatening complications of bleeding and perforation [4,5]. 
While proton pump inhibitors (PPIs) reduce the development of peptic ulcer and 
related complications in patients taking NSAIDs or/and low-dose aspirin, their 
beneficial effect, which is related to their gastric antisecretory activity [6], is not 
expected to take place beyond the duodenum [7]. The appreciation that NSAID-
associated GI damage does extend also to the lower digestive tract dates back to the 
early 90’s, when a few observational studies and the first large prevention study (i.e. 
the MUCOSA trial) were published [8]. In the more recent VIGOR trial, more than 40% 
of NSAID-related events occurred in the lower GI tract (i.e. small bowel and colon) [9].  
Over the past decade, there has been a progressive change in the overall pattern of GI 
events leading to hospitalization, with a clear decreasing trend in upper GI events and 
a slight, but significant, increase in lower GI events [10]. The availability of video 
capsule endoscopy has allowed a precise quantification of the incidence and 
characterization of small bowel damage, which appears to be time-dependent. Indeed, 
available studies [11,12] have shown that about 75% of NSAID users display intestinal 
mucosal injury, with most denuded areas identified in the proximal part of the small 
bowel and all ulcers in its distal part [13]. In healthy volunteers [12,14,15] and patients 
[11], omeprazole did not prevent NSAID-associated intestinal damage, evaluated by 
video capsule or/and fecal calprotectin measurement. Recent experimental (for review 
see [16]) and clinical [17,18] evidence suggests that PPIs may actually aggravate NSAID 
injury in the small bowel. The lack of protective effect is clearly due to the fact that 
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NSAID-enteropathy does not depend on gastric acid and is therefore not a pH-
dependent phenomenon [5].  
The pathogenesis of small intestinal damage is still not completely understood. 
Although drug-induced inhibition of mucosal prostaglandin (PG) synthesis during 
NSAID use occurs along the entire digestive tract, there are significant differences 
between the distal and proximal GI tract in the concurrence of other pathogenic 
factors that may add to mucosal damage. Among them, the absence of acid and the 
presence in the intestinal lumen of bacteria and bile, which may trigger specific NSAID-
related pathogenic mechanisms at level of the distal GI tract, are the most prominent 
ones [19]. 
 
Increasing experimental evidence suggests that inhibition of both COX-1 and COX-2 is 
necessary to cause significant GI damage [20,21,22]. However, NSAID-induced injury to 
the intestinal epithelium is set in motion by direct effects of the drug after oral 
administration, a persistent local action, due to enterohepatic circulation and systemic 
effects after absorption. Initial cellular damage is due to entrance of the usually acidic 
NSAIDs into the cell via damage to the brush border cell membrane, and disruption of 
the mitochondrial processes of oxidative phosphorylation, with consequent ATP 
deficiency [20,21,22]. This leads to increased mucosal permeability [23], which 
facilitates the entry and actions of luminal factors, such as dietary macromolecules, 
bile acids, components of pancreatic juice, and bacteria, activating the inflammatory 
cascade [20,21,22]. 
 
Amongst luminal aggressors, intestinal bacteria are the main neutrophil 
chemoattractants. Several studies [24] show that antimicrobials (tetracycline, 
kanamycin, metronidazole or neomycin plus bacitracin) attenuate NSAID-enteropathy, 
thus supporting further the pathogenic role of enteric bacteria. Additional, albeit 
indirect, support to the role of gut bacteria in the pathogenesis of NSAID-enteropathy, 
is represented by the similarity between indomethacin-induced intestinal damage and 
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Crohn’s disease (CD). Not only are the lesions both macro- and microscopically similar, 
but are they also sensitive to the same drugs (e.g. sulphasalazine, corticosteroids, 
immunosuppressants and antibiotics) [25], at least in the experimental setting. A 
recent video capsule study [26] showed also that mesalazine granules were able to 
reduce naproxen-induced intestinal damage in patients with inflammatory 
arthropaties. 
Early studies [27] showed that metronidazole (an antimicrobial targeting most Gram-
negative and Gram-positive anaerobic bacteria [28]) is able to reduce inflammation 
and blood loss in patients taking NSAIDs, thus suggesting a therapeutic potential of 
antimicrobials in this clinical setting. However, potential adverse effects of systemic 
antimicrobials and the possible occurrence of drug resistance have so far precluded 
this interesting approach [24]. 
Rifaximin (4-deoxy-4'-methylpyrido[1',2'-1,2]imidazo [5,4-c]rifamycin SV) is a synthetic 
derivative of rifamycin, characterized by very low GI absorption, while retaining a 
broad spectrum of antibacterial activity [29,30,31]. Being virtually non-absorbed, its GI 
bioavailability is high, with fecal concentrations largely exceeding minimum inhibitory 
concentrations against pathogenic enterobacteria, while its scarce impact on extra-GI 
sites minimizes the risk of antimicrobial resistance and systemic adverse events [25]. 
Upon appreciation of the pathogenic role of gut flora in several GI diseases, the use of 
rifaximin has been extended from GI infections to hepatic encephalopathy, small 
intestine bacterial overgrowth and colonic diverticular disease [25,32]. The drug is also 
being investigated in the treatment of inflammatory bowel disease [33]. 
Since rifaximin does display all the characteristics of an ideal antibiotic for targeting 
enterobacteria [34], we felt it worthwhile to assess its ability to prevent NSAID-
enteropathy in a rat model of indomethacin-induced enteropathy. To this aim, we 
selected the recently developed extended intestinal release (EIR) formulation, which 
contains microgranules of rifaximin, coated with a gastric acid-resistant polymer. This 
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formulation, under development also for the treatment of Crohn’s disease, has been 
designed to bypass the stomach and release the microgranules directly in the 
intestine, thereby increasing the local concentration of rifaximin, and to maximize its 




Experiments were performed on aged (40 week-old) male Wistar rats (500-600 g) 
(Harlan Laboratories, Udine, Italy). The animals were fed standard laboratory chow 
and tap water ad libitum, and were not employed for at least one week after their 
delivery to the laboratory. They were housed, three in a cage, in temperature-
controlled rooms on a 12-h light cycle at 22-24°C and 50-60% humidity. 
 
2.2 Experimental design 
Enteropathy was induced by indomethacin in accordance with the method previously 
developed in our laboratory [35]. The dose of indomethacin and duration of treatment 
were selected in order to obtain small bowel injuries mirroring those induced by 
NSAIDs in humans. To pursue this goal, non-fasted rats were treated for 14 days with 
indomethacin 1.5 mg/kg BID by intragastric route, suspended in 1% methylcellulose 
and administered in a volume of 0.3 ml/rat. This dose was previously shown to 
suppress COX-1 and COX-2 activity in rats by 97% and 98%, respectively [35] and to 
reduce inflammation in rat models of adjuvant arthritis [36] and carrageenan-induced 
paw edema [37]. 
The EIR formulation of rifaximin polymorph alpha (R-EIR 50 mg/kg BID) (Alfa 
Wassermann SpA, Bologna, Italy) was administered 1 hour before indomethacin for 14 
days (suspended in 1% methylcellulose, 1 ml/rat). In a subgroup of animals, treatment 
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with rifaximin was initiated 7 days before starting indomethacin administration and 
continued for 14 days until the end of treatment with the NSAID. The dose of 50 mg/kg 
BID had been found to protect against enteropathy induced by indomethacin in a 
preliminary dose-response study (25, 50 and 100 mg/kg BID). In addition, the selected 
rifaximin dose was similar to that employed in previous studies in rats [38,39]. Twenty 
four hours after the last dose of test drugs, rats were anesthetized with chloral 
hydrate. Blood samples were collected by cardiac puncture from each animal for 
hemoglobin measurement. The whole GI tract was excised and samples of jejunum 
and ileum were snap frozen in liquid nitrogen and stored at -80°C for subsequent 
analysis of myeloperoxidase (MPO), tumor necrosis factor (TNF), malondialdehyde 
(MDA) and protein carbonyl levels. Samples of ileum were also processed for the 
evaluation of bacterial phyla abundance, as reported below. Other portions of tissues 
were fixed in 10% formalin for subsequent evaluation of microscopic damage. 
Experimental groups were arranged as follows: Group 1: animals treated with vehicle 
(control, n=10); Group 2: animals treated with indomethacin 1.5 mg/kg BID (IND, 
n=15); Group 3: animals treated with indomethacin plus R-EIR (50 mg/kg BID) for 14 
days (IND+R-EIR14, n=12); Group 4: pretreatment with R-EIR (50 mg/kg BID) for 7 days, 
followed by indomethacin co-treatment with R-EIR (50 mg/kg BID) for 14 days (IND+-R-
EIR21, n=12).  
 
2.3 Microscopic assessment of intestinal damage 
Histological evaluation of small bowel injury was carried out as previously described 
[35]. Upon removal, the small intestine was immediately injected with 10% formalin 
and left in the same fixative solution. After 30 min, it was opened along the anti-
mesenteric border, cleaned of its fecal contents, and fixed again in 10% formalin for 
24 h. In order to rule out any bias, intestinal tissue samples were taken in accordance 
to the following procedure: the full length of small intestine was measured; in the 
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jejunum, two specimens of 1.5-2 cm were taken 5 cm far from both the proximal and 
distal end of 81% of the total small bowel length; in the ileum, 1 cm of tissue proximal 
to the ileo-cecal valve was discarded and two specimens of 1.5-2 cm were taken at this 
edge as well as 5 cm  from the first ileum sample. 
Sections of jejunum and ileum were embedded into paraffin blocks and cut into 3 
consecutive serial 7-8 µm sections. The slices were cut at two different points of the 
block: two on the surface and three at a deeper level. Each slice was placed on a glass 
slide for staining with haematoxylin and eosin. Histological damage was assessed by 
two observers, blind to treatments, according to the score system adopted in our 
laboratory [35]. The intestinal damage was scored as reported in Table 1. 
Representative pictures, showing the histological appearance of type 1, 2 and 3 lesions 
of jejunum and ileum, are displayed in Figure 1. 
 
2.4 Evaluation of tissue myeloperoxidase levels 
MPO, as a quantitative index to estimate the degree of intestinal wall infiltration by 
inflammatory polymorphonuclear cells, was assessed as described by Fornai et al. [35]. 
Specimens of small intestinal tissues (30 mg) were homogenized on ice with a polytron 
homogenizer (QIAGEN, Milan, Italy) in 0.6 mL of ice-cold lysis buffer (200 mM NaCl, 5 
mM EDTA, 10 mM Tris, 10% glycerine, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml 
leupeptin and 28 g/ml aprotinin (pH 7.4). The homogenate was centrifuged 2 times at 
4°C for 15 min at 1,500 g. The supernatant was diluted 1:5 and used for determination 
of MPO concentration by means of an enzyme-linked immunosorbent assay (ELISA) 
(Hycult Biotech, Uden, Netherlands). The results were expressed as nanograms of MPO 




2.5 Evaluation of tissue TNF levels 
Tissue levels of TNF, a potent inflammatory cytokine, whose intestinal production is 
increased dose-dependentely by indomethacin [40] were measured as previously 
described [41]. Briefly, samples of jejunum and ileum, collected as reported above, 
were weighed, thawed, and homogenized in 0.4 ml of PBS (0.4 ml/20 mg of tissue), pH 
7.2 at 4°C, and centrifuged at 10,000g for 5 min. Aliquots (100 μL) of the supernatants 
were then used for subsequent assay by means of a commercial ELISA kit (Abcam, 
Cambridge, UK). Tissue TNF levels were expressed as picograms per milligram of tissue. 
 
2.6 Evaluation of tissue malondialdehyde levels 
MDA concentration in intestinal tissues was determined to obtain quantitative 
estimates of membrane lipid peroxidation [35]. For this purpose, intestinal tissue was 
excised, weighed, minced by forceps, homogenized in 2 ml of cold buffer (Tris-HCl 20 
mM, pH 7.4) using a polytron homogenizer (QIAGEN, Milan, Italy), and centrifuged at 
1,500 g for 10 min at 4°C. Aliquots of supernatants were then used for subsequent 
assay procedures. Mucosal MDA concentrations were estimated using a colorimetric 
assay kit (Cayman Chemical, Ann Arbor, MI, U.S.A.). Results were expressed as nmoles 
of MDA per milligram of intestinal tissue. 
 
2.7 Evaluation of protein oxidation levels 
Oxidative stress can give rise to protein carbonyl derivatives, via a variety of 
mechanisms that include fragmentation and amine oxidation either due to metal 
catalysis or by hypochlorous acid. As a consequence, measurement of protein 
carbonyls as a marker of tissue injury has become popular [42]. In the rat intestine, the 
extent of protein oxidation was estimated using a colorimetric assay kit (Cayman 
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Chemical, Ann Arbor, MI, USA), according to Reznick & Packer [43]. Specimens of 
jejunum and ileum (30 mg) were homogenized on ice with a Polytron homogenizer 
(Qiagen, Milan, Italy) in 0.6 ml of ice-cold lysis buffer (RIPA buffer containing 1 μg/ml 
leupeptin, and 28 μg/ml aprotinin, pH 7.4). The homogenate was centrifuged at 4°C for 
10 minutes at 1,600g. Aliquots (200 μL) of supernatants were then used for 
subsequent assay procedures. Results were expressed as nanomoles of carbonyl 
content  per milligram of proteins. 
 
2.8 Assessment of blood haemoglobin concentration 
Haemoglobin analysis was performed on blood samples, collected as reported above, 
by means of Quantichrom Hemoglobin assay kit (Bioassay Systems, Hayward, CA, USA) 
and expressed as g/dL. 
 
2.9 DNA extraction and metagenomic analysis of bacterial population in ileal tissue 
DNA was extracted from 250 mg of ileal tissue using the QIAamp DNA Mini kit (Qiagen, 
Hildens, Germany) and following the manufacturer’s instructions. The final elution 
volume was 200 µl, the DNA concentration was determined by absorbance at 260 nm 
(A260), and the purity was estimated by determining the A260/A280 ratio with a 
spectrophotometer. Extracted DNA was adjusted to a final concentration of 40 ng/μl. 
Genomic DNA from pure bacterial cultures was extracted using Wizard Genomic DNA 
Purification Kit (Promega Corporation, Wisconsin, USA) according to the 
manufacturer’s instructions. 
Total DNA extracted from ileal tissue was analyzed for the mucosal-associated 
microbiota through 16S rDNA metagenomics (MiSeq). Metagenomic analysis was 
performed with MiSeq, Illumina platform at GenProbio SRL (Parma, Italy). Amplicons of 
the V3-V4 bacterial 16S rRNA gene region were obtained and sequenced using the 
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Illumina MiSeq platform, according to Illumina specific protocols. The number of 
sequences and operational taxonomic units (OTUs) for each sample were calculated 
using Quantitative Insights Into Microbial Ecology software (QIIME, 
http://qiime.org/scripts/version1.9.1) and taxonomic classification on Silva v. 119 
database was assessed.  
 
 2.10 Statistical analysis 
Results are presented as mean ± standard error of mean (S.E.M.). The statistical 
significance of data was evaluated by one way analysis of variance (ANOVA) followed 
by post hoc analysis by Student–Newman–Keuls test, and p values less than 0.05 were 
considered significant. All statistical calculations were performed using GraphPad 
Prism™ 3.0 software (GraphPad, San Diego, CA, USA).  
 
3. Results 
3.1 Mortality Rate 
At the end of the treatment period, the group treated with indomethacin displayed a 
13.3% mortality rate (Table 2). In both groups of animals treated with rifaximin 
(IND+R-EIR14 or IND+R-EIR21) the mortality rate was lower (i.e. 8.3%), albeit not 
significantly (Table 2).  
 
3.2 Macroscopic Appearance of the Intestine 
Owing to the large extension of intestinal mucosal surface, it was quite difficult to 
perform a reliable quantitative estimation of the macroscopic injury elicited by 
indomethacin. However, qualitative inspection allowed to detect macroscopic 
alterations, including diaphragm-like strictures and multiple ulcerative lesions in 
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animals treated with this NSAID. By contrast, no appreciable macroscopic changes 
were evident in intestinal tissues from rats treated with indomethacin plus rifaximin. 
 
3.3 Microscopic assessment of intestinal damage 
3.3.1 Effects of indomethacin  
In the jejunum and ileum from control animals, microscopic examination did not reveal 
any type of lesion (Figure 2 and 3). Administration of indomethacin (1.5 mg/kg BID) for 
14 days was associated with the occurrence of type 1, 2 and 3 lesions in both jejunum 
and ileum (Figure 2 and 3). 
3.3.2 Effects of rifaximin on indomethacin-induced intestinal damage 
R-EIR alone did not cause any mucosal injury and did not modify any of study 
parameters (data not shown), with the sole exception of bacterial population. 
In the jejunum from rats of groups IND+R-EIR14 or IND+R-EIR21 the rates of type I, type 
II or type III lesions were significantly decreased or not present at all, as compared with 
the group treated with IND alone (Figure 2). Likewise, in the ileum from animals of 
groups IND+R-EIR14 or IND+R-EIR21, indomethacin-induced lesions displayed a 
significant decrease or were not evident at all, as compared with animals treated with 
indomethacin alone (Figure 3). 
 
3.4 Tissue MPO levels 
3.4.1 Effects of indomethacin  
MPO levels in jejunal specimens excised from control rats were 9.74 ng/mg of tissue. 
In animals treated with indomethacin (1.5 mg/kg BID) for 14 days, MPO concentrations 
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were significantly increased (Figure 4A). In the ileum, MPO concentration in control 
animals was 7.48 ng/mg of tissue, and the administration of indomethacin (1.5 mg/kg 
BID) for 14 days was associated with a significant increase in MPO (Figure 4B). 
 
3.4.2 Effects of rifaximin 
In the jejunum from rats of groups IND+R-EIR14 or IND+R-EIR21, tissue MPO levels were 
similar to those estimated in control rats, and significantly lower, as compared with 
MPO concentrations in jejunal tissues from indomethacin-treated animals (Figure 4A). 
Likewise, in the ileum from rats of groups IND+R-EIR14 or IND+R-EIR21, there was a 
significant decrease in MPO concentration, as compared with animals treated with 
indomethacin alone (Figure 4B).  
 
3.5 Tissue TNF levels 
3.5.1 Effects of indomethacin 
TNF levels in jejunum from control rats accounted for 2.37 pg/mg of tissue. The 
administration of indomethacin (1.5 mg/kg BID) for 14 days was associated with a 
significant increase in TNF concentration (Figure 5A). In the ileum, tissue TNF levels in 
control rats were 2.09 pg/mg of tissue. In rats treated with indomethacin there was a 
significant increment of this cytokine (Figure 5B). 
 
3.5.2 Effects of rifaximin 
Rats treated with IND+R-EIR14 or IND+R-EIR21 displayed a significand decrease in tissue 
TNF levels both in jejunum and ileum, compared with animals treated with 
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indomethacin alone, showing values not significantly different from those observed in 
control animals (Figure 5A and B). 
 
3.6 Tissue MDA levels 
3.6.1 Effects of indomethacin  
In the jejunum of control rats, MDA concentration was 28.23 nmol/mg of tissue. 
Animals treated with indomethacin (1.5 mg/kg BID) for 14 days displayed significant 
increments of tissue MDA concentrations (Figure 6A). In the ileum, MDA levels in 
tissue samples from control animals were 20.63 nmol/mg of tissue. These levels were 
significantly increased by indomethacin (Figure 6B). 
 
3.6.2 Effects of rifaximin  
In animals of groups IND+R-EIR14 or IND+R-EIR21 a significant decrease in MDA levels 
was observed both in the jejunum and ileum, as compared with indomethacin alone, 
with values similar to those estimated in intestinal tissues from control animals (Figure 
6A and B).  
 
3.7 Protein carbonyl levels 
3.7.1 Effects of indomethacin 
The tissue amounts of protein carbonyl in jejunum and ileum form control rats were 
18.74 and 19.24 nmol/mg of proteins, respectively. The administration of 
indomethacin (1.5 mg/kg BID) for 14 days elicited a significant increase in protein 
carbonyl levels both in jejunum and ileum (Figure 7A and B). 
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3.7.2 Effects of rifaximin 
In rats treated with IND+R-EIR14 or IND+R-EIR21, there was a significant decrease in 
tissue protein carbonyl levels both in jejunum and ileum, with values not significantly 
different from those assessed in control tissues (Figure 7A and B). 
 
3.8 Hemoglobin blood levels 
Animals treated with indomethacin (1.5 mg/kg BID) for 14 days displayed a significant 
decrease in blood hemoglobin concentration, as compared with controls. In rats of 
groups IND+R-EIR14 or IND+R-EIR21, hemoglobin levels were significantly higher than 
those measured in the group treated with indomethacin alone (Figure 8). Under 
rifaximin, however, the hemoglobin levels of indomethacin-treated rats were still 
lower than those of control animals, likely because upper GI bleeding was not affected 
by the antibiotic. 
 
3.9 Abundance of Proteobacteria, Firmicutes and Bacterioidetes in the ileum 
In control animals, the relative abundance of Proteobacteria, Firmicutes and 
Bacterioidetes was 10.4, 23.5 and 14.4%, respectively. Treatment with indomethacin 
(1.5 mg/kg BID) for 14 days was associated with an increase in the relative abundance 
of Proteobacteria and Firmicutes and a slight decrease in Bacterioidetes (Figure 9). In 
rats treated with IND+R-EIR14, the relative abundance of such phyla returned toward 






Results of the present investigation clearly show that rifaximin administration along 
with indomethacin protects the small bowel from the damaging effect of this NSAID. 
Despite a previous, small study in guinea-pigs [44] reported a protective effect of this 
antibiotic on indomethacin-induced intestinal damage, the predictive value of the 
experimental model adopted (as well as the drug regimens) is of limited (if any) 
relevance to clinical settings. 
The present study was conducted on aged rats, since ageing is a risk factor for NSAID-
induced enteropathy [45,46]. Indeed, elderly patients could display altered basal 
conditions as a consequence of aging and/or co-morbidities and co-therapies. 
Moreover, our model was set up to mirror clinical practice with NSAID chronic 
administration in humans, and indeed the present indomethacin regimen caused small 
bowel alterations, such as diaphragm-like strictures and multiple erosive lesions, 
together with a decrease in blood hemoglobin, known to occur in patients receiving 
chronic NSAID therapy [12]. Of note, repeated administration of low dose (i.e. 3 
mg/kg) indomethacin, besides mimicking regimens adopted in clinical practice, has 
been shown to ensure intraluminal indomethacin concentrations, high enough to elicit 
consistent small bowel mucosal damage [47]. 
The majority of experimental studies on NSAID-enteropathy have used single, high-
dose indomethacin administration to induce mucosal damage.  In these models, the 
injury pattern consists mainly of multiple, hemorrhagic lesions involving the full 
thickness of intestinal wall [48,49,50], a picture that differ greatly from the ones seen 
at enteroscopy or video capsule endoscopy in patients taking NSAIDs chronically 
[11,12,13]. Most importantly, these acute models of intestinal damage may be not 
suitable to evaluate the protective effect of poorly absorbed antibiotics, like rifaximin, 
which need at least 7-10 days to consistently affect intestinal bacterial load, 
composition and activity [51]. Last but not least, guinea-pig is not considered a 
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reference species to implement a model of NSAID-enteropathy. As matter of fact, 
guinea-pigs have been mostly used for in vivo or in vitro studies to evaluate the effect 
of indomethacin on intestinal neuromuscular functions [52,53,54], while in vivo 
models of enteropathy have been developed in rats or mice, including transgenic 
animals. All the above drawbacks strongly limit the translational value of the guinea-
pig acute model and the respective results. 
Over 40 years ago, Robert and Asano [55] showed for the first time that germ-free rats 
are resistant to the intestinal damaging effect of indomethacin, becoming sensitive 
again to such NSAID when mono-contaminated with E. coli. On the other hand, oral 
administration of indomethacin is followed by a time-dependent bacterial invasion of 
intestinal mucosa (with increase in both aerobic and anaerobic strains) [56], which is 
facilitated by the drug-induced increase in intestinal permeability that is also time-
dependent [57]. Enterobacteria then trigger toll-like receptors, whose activation is 
followed by an increased mucosal expression of inflammatory cytokines [58]. This 
elicits neutrophil recruitment with subsequent release of proteases and reactive 
oxygen species (ROS) leading ultimately to mucosal injury [19]. 
In line with the above-outlined sequence of pathogenic events, we found that 
indomethacin did increase mucosal inflammation, as reflected by the increased MPO 
and TNF tissue concentrations, thus confirming previous findings [35,59]. Likewise, 
lipid and protein peroxidation, mirrored by elevated MDA and  protein carbonyl levels, 
respectively, also increased after the NSAID administration. 
Current prevention strategies to reduce the extent of damage in the upper GI tract are 
not effective in the lower GI one. While therapy with celecoxib (a non acidic, COX-2 
selective inhibitor) is safer than that with conventional NSAIDs [7], the dose-
dependent increase in the risk of severe CV events associated with long-term therapy 
with this class of drugs is of concern in patients with CV risk factors. New alternatives, 
including the use of selective and poorly absorbed antibiotics, like rifaximin, probiotics 
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or prebiotics, are therefore important avenues to explore with the aim of correcting 
the shift of intestinal microflora towards pro-inflammatory Gram-negative bacteria 
[19]. Although current clinical support to this view is still weak, therapeutic 
manipulation of luminal microecology is particularly attractive as a physiologic, non-
toxic approach to prevent, if not to treat, NSAID enteropathy.   
 
Being the prevalence of small intestine bacterial overgrowth (SIBO) high in patients on 
long-term NSAID therapy [60], the use of rifaximin appears to be an even more 
rational choice for prevention of NSAID-enteropathy. Indeed, this poorly absorbed 
antibiotic is very effective and widely adopted for treatment of SIBO [61,62], whose 
occurrence correlates with the severity of intestinal damage [60]. 
Our results demonstrate that rifaximin significantly prevents indomethacin-induced 
intestinal damage, as documented by macro and microscopic assessment as well as 
digestive bleeding. This entero-protective effect was associated with a decrease in 
tissue inflammation (i.e. MPO and TNF mucosal concentrations) and oxidative stress 
(i.e. MDA and protein carbonyl tissue levels). These findings are consistent with those 
obtained in our laboratories with diclofenac-enteropathy [63]. Under similar 
experimental conditions, rifaximin was also able to reduce the NSAID-induced increase 
in fecal calprotectin as well as to counterbalance the overexpression of TLR-4 and TLR-
2 in the intestinal mucosa [63]. Along the same lines, a video capsule study in healthy 
volunteers [64] has recently shown an overall protective effect of rifaximin EIR on 
diclofenac-associated intestinal mucosal lesions. Interestingly enough, our 
experiments have shown that pre-treatment with rifaximin for 7 days prior to 
indomethacin administration does not add further protection in comparison to what 
observed when the antibiotic administration was started together with the NSAID, 
thus suggesting that a priming effect on enteric microflora is not needed. And indeed, 
the pivotal clinical trial [64] confirmed that rifaxmin co-administration with NSAID is 
effective in affording intestinal protection. The clinical implications of these findings 
are important since pre-administration of a protective agent would delay the start 
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(and benefits) of anti-inflammatory therapy and its co-administration would improve 
compliance. 
The entero-protective effect of rifaximin likely depends on its broad spectrum of 
antibacterial activity, including Gram-positive and Gram-negative bacteria, both 
aerobes and anaerobes [32]. More recent experimental studies [65,66] not only 
confirmed that rifaximin reduces the total bacterial load, but also modulates bacterial 
community composition, increasing the relative abundance of Lactobacillaceae. This 
peculiar property was associated with a reduction of intestinal inflammation and 
alterations in intestinal permeability [66]. Along the same lines, rifaximin co-treatment 
was able – under our experimental conditions – to counterbalance the inflammation as 
well as lipid and protein peroxidation induced by indomethacin in the rat small bowel. 
Rifaximin-induced changes in bacterial composition my also impact on indomethacin 
pharmacokinetics within the intestinal lumen via reduction of the cleavage of its 
aglicone by bacterial beta-glucuronidase [67,68]. This would decrease the drug uptake 
by enterocytes and, consequently, impair entero-hepatic circulation, which prolongs 
the mucosal noxious activity of the NSAID. 
The anti-inflammatory activity of rifaximin could be either indirect (i.e. a consequence 
of its antimicrobial properties) or direct in nature. Indeed, besides the antibiotic 
activity, this drug is endowed with an intrinsic anti-inflammatory activity, which seems 
to be class-dependent. Rifamycins indeed inhibit human neutrophil functions [69,70] 
and early studies have indeed shown that intra-articular rifamycin is an effective 
compound in patients in chronic arthritides, like juvenile rheumatoid arthritis and 
ankylosing spondylitis [71]. This anti-inflammatory, which was mirrored in our study by 
a significant decrease in MPO (and TNF) tissue levels, could translate into a reduction 
of MPO-induced formation of indomethacin reactive metabolites [72]. 
Recent evidence points out that – besides non-antimicrobial activities – rifaximin 
displays also “eubiotic” properties. Indeed, in patients with inflammatory conditions 
(like inflammatory bowel disease, colonic diverticular disease or hepatic 
 21 
encephalopathy), rifaximin - while not altering the overall structure of human colonic 
microbiota - increased the relative abundance of Bifidobacteria and Lactobacilli 
[73,74]. Similarly, our study found that rifaximin was able to counterbalance the 
increase in Proteobacteria and Firmicutes abundance induced by indomethacin 
administration. Recent investigations [75] found a marked increase in Proteobacteria 
in naproxen-treated rats and suggested that these microbial changes may contribute 
to NSAIS-induced intestinal damage. 
Rifaximin in the prevention of NSAID-enteropathy should clearly used long-term. As for 
every drug used in the long-term, safety - besides efficacy - is of paramount 
importance. Rifaximin proved to be extremely safe, even when given continuously (at 
standard therapeutic doses) for 6 months and its minimal, if any, systemic absorption 
(not exceeding 1%) accounts for the adverse event profile, which overlapped that of 
placebo [76]. In addition, long-term studies in IBS patients have shown that there were 
no clinically relevant changes in bacterial sensitivity to other antibiotic classes, no 
emergence of pathogenic bacteria, no occurrence of opportunistic infections, and no 
alteration of the overall microbiota [77].  
In summary, co-administration of rifaximin with indomethacin can prevent NSAID-
induced small bowel damage. Although the mechanisms need to be further elucidated, 
other experimental [63] and clinical [64] studies lend support to the present 
conclusions and suggest that targeting enteric bacteria by a poorly absorbed antibiotic 
is an attractive therapeutic avenue for the prevention of NSAID-enteropathy [19]. 
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Figure 1. Representative pictures showing the histological appearance of type 1, 2 and 
3 lesions elicited by indomethacin in the jejunum (a) and ileum (b). Asterisks in the 
higher magnificated pictures (right) indicate a significant thickening of the submucosal 
layer with the presence of inflammatory infiltration and vasodilation. In particular, in 
the jejunal type 3 lesion a marked thickening of the whole gut wall can be observed, 




Figure 2. Histomorphometric analysis of damage in the jejunum of rats treated with 
vehicle (CONTROL), indomethacin (IND, 1.5 mg/kg BID), indomethacin plus rifaximin-
EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 7 days followed by indomethacin plus 
rifaximin (IND+R-EIR21) for 14 days. Each column represents the mean ± S.E.M. 
obtained from 10-13 animals. *P<0.05; significant difference vs CONTROL; ap<0.05, 




Figure 3. Histomorphometric analysis of damage in the ileum of rats treated with 
vehicle (CONTROL), indomethacin (IND, 1.5 mg/kg BID), indomethacin plus rifaximin-
EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 7 days followed by indomethacin plus 
rifaximin (IND+R-EIR21) for 14 days. Each column represents the mean ± S.E.M. 
obtained from 10-13 animals. *p<0.05; significant difference versus control; ap<0.05, 




Figure 4. Effects of vehicle (CONTROL), indomethacin (IND, 1.5 mg/kg BID), 
indomethacin plus rifaximin-EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 7 days 
followed by indomethacin plus rifaximin (IND+R-EIR21) for 14 days on tissue 
myeloperoxidase (MPO) levels in the jejunum (A) or ileum (B). Each column represents 
the mean ± S.E.M. obtained from 10-13 animals. *p<0.05, significant difference versus 




Figure 5. Effects of vehicle (CONTROL), indomethacin (IND, 1.5 mg/kg BID), 
indomethacin plus rifaximin-EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 7 days 
followed by indomethacin plus rifaximin (IND+R-EIR21) for 14 days on tissue tumor 
necrosis factor (TNF) in the jejunum (A) or ileum (B). Each column represents the mean 




Figure 6. Effects of vehicle (CONTROL), indomethacin (IND, 1.5 mg/kg BID), 
indomethacin plus rifaximin-EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 7 days 
followed by indomethacin plus rifaximin (IND+R-EIR21) for 14 days on tissue 
malondialdehyde (MDA) in the jejunum (A) or ileum (B). Each column represents the 
mean ± S.E.M. obtained from 10-13 animals. *p<0.05, significant difference versus 




Figure 7. Effects of vehicle (CONTROL), indomethacin (IND, 1.5 mg/kg BID), 
indomethacin plus rifaximin-EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 7 days 
followed by indomethacin plus rifaximin (IND+R-EIR21) for 14 days on tissue protein 
carbonyl content in the jejunum (A) or ileum (B). Each column represents the mean ± 




Figure 8. Effects of vehicle (CONTROL), indomethacin (IND, 1.5 mg/kg BID), 
indomethacin plus rifaximin-EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 7 days 
followed by indomethacin plus rifaximin (IND+R-EIR21) for 14 days on blood 
hemoglobin levels. Each column represents the mean ± S.E.M. obtained from 10-13 
animals. *p<0.05, significant difference versus control; ap<0.05, significant difference 




Figure 9. Relative abundance of Proteobacteria, Firmicutes and Bacterioidetes in ileal 
tissues obtained from rats treated with vehicle (CONTROL), indomethacin (IND, 1.5 
mg/kg BID), indomethacin plus rifaximin-EIR (IND+R-EIR14), or R-EIR (50 mg/kg BID) for 





Table 1. Microscopic criteria for quantitative estimation of the intestinal injury 




 Damage confined to the tunica mucosa 
 De-epithelization 
 Significant morphological alterations of the villi 
Type 2 
injury 
 Inflammatory infiltration in the submucosa, with thickening of the tunica muscolaris 
or serosa 
 The morphologic framework of tunica mucosa is preserved 
Type 3 
injury 
 Damage involves the full thickness of intestinal wall 
 The morphologic patterns of tunicae are lost 
 Inflammatory reaction widely extended to the tunica serosa with a significant 





Table 2. Mortality rates in the groups of treatment 
Treatment Dose 
(mg/kg/day) 
N Mortality (%) 
CONTROL - 10 (0/10) 0 
IND 3 15 (2/15) 13.3 
IND+R-EIR14 3+100 12 (1/12) 8.3 
IND+R-EIR21 3+100 12 (1/12) 8.3 
 
 
 
